Australian Clinical Labs falls after Healius rejects buyout bid
** Shares of Australian Clinical Labs ACL.AX fall as much
as 5% to A$3.450, set to mark worst day since March 27, if
current losses hold
** Stock hits lowest since April 18
** Fall comes after Australia's Healius HLS.AX recommended
its shareholders to reject a takeover offer by co
** Healius shares are down ~1.5%
** ACL has risen ~22% this year, as of last close
($1 = 1.4945 Australian dollars)
(Reporting by Nausheen Thusoo in Bengaluru)
((Nausheen.Thusoo@thomsonreuters.com;))
Recent news on Healius
See all newsAustralia's Healius rises on sale of unit Agilex; Jefferies lifts PT
Brief: Healius To Sell Agilex Biolabs To Novotech
Australia's Healius rises on sale of unit Agilex Biolabs to Novotech Health
Brief: Healius Requests Trading Halt
Brief: Healius Expects To Achieve T27 Target Of Mid-To-High Single-Digit EBIT Margins By Dec 2028